Centene (NYSE:CNC) Hasn't Managed To Accelerate Its Returns
Barclays Maintains Centene(CNC.US) With Buy Rating, Cuts Target Price to $90
How Is Centene's Stock Performance Compared to Other Healthcare Stocks?
Barclays Adjusts Price Target on Centene to $90 From $104, Maintains Overweight Rating
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Here's Why We Think Centene (NYSE:CNC) Might Deserve Your Attention Today
How Is The Market Feeling About Centene?
Goldman's Top 50 High Sharpe Ratio Stocks
Centene Price Target Maintained With a $110.00/Share by Oppenheimer
Navigating 11 Analyst Ratings For Centene
Oppenheimer Maintains Centene(CNC.US) With Buy Rating, Maintains Target Price $110
Why Centene (CNC) Is a Top Value Stock for the Long-Term
Here's How Much You Would Have Made Owning Centene Stock In The Last 10 Years
Federal Government to Revise Medicare Advantage Plans Ratings
Cantor Fitzgerald Maintains Centene(CNC.US) With Buy Rating, Maintains Target Price $90
Centene Price Target Maintained With a $90.00/Share by Cantor Fitzgerald
Express News | Cantor Fitzgerald Reiterates Overweight on Centene, Maintains $90 Price Target
Pro Football Hall of Fame, Coordinated Care, Seattle Seahawks and Other Local Partners Host 'Strong Youth Strong Communities' Summit to Bring Message of Resilience and Inspiration to Washington Youth
Cigna Expects Higher Inpatient Medical Activity Throughout 2024
Investors in Centene (NYSE:CNC) Have Seen Notable Returns of 30% Over the Past Five Years